Tech Company Financing Transactions
Leal Therapeutics Funding Round
Newpath Partners, Alexandria Venture Investments and Euclidean Capital participated in a $45 million venture round for Leal Therapeutics. This venture round was announced on 10/30/2024.
Transaction Overview
Company Name
Announced On
10/30/2024
Transaction Type
Venture Equity
Amount
$45,000,000
Round
Undisclosed
Investors
Newpath Partners (Lead Investor) (Thomas Cahill)
Proceeds Purpose
The company intends to use the funds to advance its pipeline of antisense oligonucleotide (ASO) and small molecule therapeutics for patients with CNS disorders.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
Undisclosed
Worcester, MA Undisclosed
USA
Worcester, MA Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Developing novel therapeutics for patients with major disorders of the central nervous system.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Asa Abeliovich
Browse more venture capital transactions:
Prev: 10/30/2024: Tilled venture capital transaction
Next: 10/30/2024: Third Wave Automation venture capital transaction
Share this article
About Database of VC Transactions
We do our best to record every notable VC transaction. VC transactions reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs